[DISCLOSURE]
Celltrion (068270) announced on Sept. 20 that it has signed a 134.9 billion won (US$120.40 million) contract with its affiliate Celltrion Healthcare to provide biosimilar antibody Remsima.
This amounts to 22.36 percent of its revenue last year and the contract expires on Sept. 30.
(
theinvestor@heraldcorp.com)
![[H.eco Forum] H.eco Forum calls for transition to clean, carbon-free energy](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=645&simg=/content/image/2024/05/22/20240522050668_0.jpg&u=20240522175145)
![[Exclusive] LACMA admits it needs further research on donated Korean paintings](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=645&simg=/content/image/2024/05/22/20240522050568_0.jpg&u=20240523001632)
![[Bridge to Africa] Africa-Korea partnership: Why it matters for future](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=645&simg=/content/image/2024/05/22/20240522050681_0.jpg&u=20240522182351)
![[Herald Interview] Korean adoptees embark on journeys to find roots](http://res.heraldm.com/phpwas/restmb_idxmake.php?idx=645&simg=/content/image/2024/05/22/20240522050754_0.jpg&u=20240522190539)